SCHEMBL24596289

SCHEMBL24596289

O=C(O)c1ccc(C(F)(F)F)cc1Nc1cccnc1C1CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 4/20 0.51
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
AKR1B1 P15121 1/20 0.47
AKR1C4 P17516 1/20 0.47
AKR1C1 Q04828 1/20 0.47
DHODH Q02127 2/20 0.46
MEN1 O00255 1/20 0.46
GMNN O75496 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
TTR P02766 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
UGT1A1 P22309 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853133 0.81 TAS2R14 (0.62) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL24596367 0.79 DHODH (0.47) TAS2R14DHODHMEN1GMNNALDH1A1
SCHEMBL30294291 0.74 LIPC (0.50) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL22852805 0.74 TAS2R14 (0.52) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL28978590 0.72 MPO (0.67) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL24596290 0.71 MAPT (0.38) TAS2R14MEN1CYP1A2CYP2C9KMT2A
SCHEMBL16737125 0.71 TAS2R14 (0.61) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL14670349 0.71 TAS2R14 (0.68) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL6813056 0.71 TAS2R14 (0.77) TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4
SCHEMBL38660631 0.71 NNMT (0.44) TAS2R14DHODHMEN1GMNNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A TAS2R14 3543/4885AKR1C3 1579/4885AKR1C2 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.